CDX2 and neoplasm: The result was a statistically significant model (p < 0.001, Chi-Squared = 45.9, Cox & Snell R2 = 0.128, Nagelkerke R2 = 0.362) identifying poor tumor differentiation and MLH1/PMS2 heterodimer deficiency as potential predictors for CDX2 expression loss (Table 3) [95.83% of all cases were correctly classified (Hosmer and Lemeshow test, p = 0.567)].